Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newron Pharmaceuticals SpAXSWX:NWRN +2.30%75 3-Year EBITDA Growth Rate is 21.00% as of Dec. 2025, which is 43% above its 10-year median of 14.70. GuruFocus rates XSWX:NWRN with a GF Score™ of 75/100 and a GF Value™ of CHF13.31 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,129 Biotechnology companies, Newron Pharmaceuticals SpA ranks better than 57.4% on this metric.
During the past 12 months, Newron Pharmaceuticals SpA's average EBITDA Per Share Growth Rate was -130.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Newron Pharmaceuticals SpA was 59.60% per year. The lowest was -71.50% per year. And the median was 14.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Newron Pharmaceuticals SpA 3-Year EBITDA Growth Rate Related Terms
XSWX:NWRN vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 21.00% mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a 3-Year EBITDA Growth Rate of 21.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Newron Pharmaceuticals SpA and its competitors. This is 43% above median its historical median of 14.70. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #481 out of 1129 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Newron Pharmaceuticals SpA's 3-Year EBITDA Growth Rate too high?
Newron Pharmaceuticals SpA's current 3-Year EBITDA Growth Rate of 21.00% is 43% above median its 10-year median of 14.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Newron Pharmaceuticals SpA's value of 21.00% is 40.9% above this industry median. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #481 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #481 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Newron Pharmaceuticals SpA in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Newron Pharmaceuticals SpA's value of 21.00% is 40.9% above this benchmark. While the company's 10-year median is 14.70 vs. the industry median of 14.90, Newron Pharmaceuticals SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newron Pharmaceuticals SpA's current 3-Year EBITDA Growth Rate of 21.00% is 40.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Newron Pharmaceuticals SpA and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current 3-Year EBITDA Growth Rate is 21.00%, which is 43% above median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF13.31, compared to a current price of CHF12.48 — trading 6.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 21.00%, which is 43% above median its 10-year median of 14.70 and 40.9% above the Biotechnology industry median of 14.90. Newron Pharmaceuticals SpA's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current 3-Year EBITDA Growth Rate is 21.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of CHF12.48 is trading 6.2% below its estimated GF Value™ of CHF13.31.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for XSWX:NWRN:
3-Year EBITDA Growth Rate: 21.00% (43% above median its 10-year median of 14.70)
GF Value™: CHF13.31 vs. price of CHF12.48 (6.2% below fair value)
Industry Position: 40.9% above the Biotechnology median (#481 of 1129)
No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
75GF Score
Get the complete analysis for XSWX:NWRN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NWRN has been successfully added to your 
